The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer

Laryngoscope

Volumn 119, Issue 1, 2009, Pages 82-88

  Saito, Koichiro ^a   Khan, Khurram ^a   Yu, Shu Zhen ^b   Ronson, Steve ^b   Rhee, Joung ^b   Li, Gouyan ^b   Van Echo, David ^b   Suntharalingam, Mohan ^b   O'Malley Jr , Bert W ^a   Li, Daqing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Capecitabine; Dihydropyrimidine dehydrogenase; HNSCC; Thymidine phosphorylase

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; THYMIDINE PHOSPHORYLASE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRANSGENE; ANIMAL; BAGG ALBINO MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; HEAD AND NECK TUMOR; NONPARAMETRIC TEST; NUDE MOUSE; PREDICTION AND FORECASTING; REGRESSION ANALYSIS; TUMOR CELL CULTURE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; THYMIDINE PHOSPHORYLASE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 63249093930     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20003     Document Type: Article

References (15)

1. American Cancer Society; 2006.
2. Malet-Martino M., Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7:288-323.
3. Ishikawa T., Fukase Y., Yamamoto T., Sekiguchi F., Ishitsuka H. Antitumor activities of a novel fluoropyrimidine, 4-pentyloxycarbonyl-5'-deoxy-5- fluorocytidine (capecitabine). Biol Pharm Bull 1998; 21:713-717.
4. Hitt R., Jimeno A., Rodriguez-Pinilla M., et al. Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer 2004; 91:2005-2011.
5. Kim JG, Sohn SK, Kim DH, et al. Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2005; 93:1117-1121.
6. Ishikawa T., Utoh M., Sawada N., et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55:1091-1097.
7. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-338.
8. Terashima M., Fujiwara H., Takagane A., et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 2002; 38:2375-2381.
9. Nishimura G., Terada I., Kobayashi T., et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 2002; 9:479-482.
10. Tran HM, Shi G., Li G., Carney JP, et al. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer. Otolaryngol Head Neck Surg 2004; 131:477-484.
11. Patterson AV, Zhang H., Moghaddam A., et al. Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 1995; 72:669-675.
12. Kanyama H., Tomita N., Yamano T., et al. Enhancement of the anti-tumor effect of 5'-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells. Jpn J Cancer Res 1999; 90:454-459.
13. Morita T., Matsuzaki A., Tokue A. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 2001; 92:451-456.
14. Usuki K., Saras J., Waltenberger J., et al. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun 1992; 184: 1311-1316.
15. Koukourakis MI, Giatromanolaki A., Fountzilas G., Sivridis E., Gatter KC, Harris AL. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res 2000; 6:381-389.